论文部分内容阅读
目的:探讨多肿瘤标志物蛋白质芯片检测系统在筛查高危人群前列腺癌发生中的作用。方法:采用多肿瘤标志物蛋白质芯片检测系统检测泌尿外科189例前列腺疾病患者血清中12种肿瘤标志物CA19-9、CA242、CEA、AFP、NSE、Ferritin、β-HCG、fPSA、tPSA、CA125、CA15-3、HGH的含量。结果:189例前列腺疾病患者血清中,fPSA和tPSA升高超过正常者分别为15.3%(29/189)和39.7%(75/189),病理诊断前列腺癌共13例,fPSA和tPSA联合诊断前列腺癌的敏感性和特异性分别为100%(13/13)和64.8%(114/176)。结论:多肿瘤标志物蛋白质芯片检测系统是进行快速和规模性筛查前列腺癌的可行和有效手段。
Objective: To explore the role of multiple tumor marker protein chip detection system in the screening of prostate cancer in high-risk groups. Methods: Tumor markers of CA19-9, CA242, CEA, AFP, NSE, Ferritin, β-HCG, fPSA, tPSA, CA125 and CA125 in sera of 189 patients with prostatic diseases were detected by multi-tumor marker protein chip detection system. CA15-3, HGH content. Results: The serum levels of fPSA and tPSA in 189 patients with prostate disease were 15.3% (29/189) and 39.7% (75/189), respectively. Thirteen patients were diagnosed as prostate cancer by pathological examination and prostate was diagnosed by fPSA and tPSA The sensitivity and specificity of cancer were 100% (13/13) and 64.8% (114/176), respectively. Conclusion: The multi-tumor marker protein chip detection system is a feasible and effective method for rapid and large-scale screening of prostate cancer.